{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:03:33Z","timestamp":1793793813725,"version":"4.6.1"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["2022R1A5A8023404"],"award-info":[{"award-number":["2022R1A5A8023404"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2024-00338853"],"award-info":[{"award-number":["RS-2024-00338853"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.mtbio.2025.102584","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:08:33Z","timestamp":1763766513000},"page":"102584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4177-7533","authenticated-orcid":false,"given":"Manoj","family":"Dalabehera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6665-3432","authenticated-orcid":false,"given":"Satyajit","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Kumar","family":"Chellappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Ale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9132-1507","authenticated-orcid":false,"given":"Neelam","family":"Poonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra Narayan","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet Kaur","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8046-7218","authenticated-orcid":false,"given":"Hae Gyun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib1","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","article-title":"The progress and promise of RNA medicine \u2013 an arsenal of targeted treatments","volume":"65","author":"Sasso","year":"2022","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.mtbio.2025.102584_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.mtbio.2025.102584_bib3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.mtbio.2025.102584_bib4","article-title":"Targeted nonviral delivery of genome editors in vivo","volume":"121","author":"Tsuchida","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.mtbio.2025.102584_bib5","article-title":"Recent advances in nanoparticulate RNA delivery systems","volume":"121","author":"Witten","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib6","first-page":"76","article-title":"Strategies for non-viral vectors targeting organs beyond the liver","volume":"18","author":"Kim","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.mtbio.2025.102584_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"issue":"10","key":"10.1016\/j.mtbio.2025.102584_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2025.102584_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41563-024-02114-5","article-title":"Blood\u2013brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system","author":"Wang","year":"2025","journal-title":"Nat. Mater."},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a phase 1\/2 clinical study of MRT5005","volume":"22","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.mtbio.2025.102584_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120681","article-title":"Treatment of ischemic neuronal death by introducing brain-derived neurotrophic factor mRNA using polyplex nanomicelle","volume":"270","author":"Fukushima","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2025.102584_bib12","article-title":"Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer's disease","volume":"466","author":"Li","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.mtbio.2025.102584_bib13","first-page":"60","volume":"9","year":"2024","journal-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical trials. Signal Transduct Target Ther"},{"issue":"40","key":"10.1016\/j.mtbio.2025.102584_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202507657","article-title":"Reengineering endogenous targeting lipid nanoparticles (ENDO) for systemic delivery of mRNA to pancreas","volume":"37","author":"Isaac","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2025.102584_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jconrel.2024.09.020","article-title":"LNP-mRNA vaccine prevents type 1 diabetes in Non-obese diabetic mice","volume":"375","author":"Chen","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2025.102584_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.omtn.2022.04.010","article-title":"Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced Obese mice","volume":"28","author":"Bartesaghi","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib17","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.mtbio.2025.102584_bib18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.mtbio.2025.102584_bib19","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2025.102584_bib20","article-title":"Advances in manufacturing technologies for lipid nanoparticles and their implications for RNA delivery","volume":"175","author":"Chen","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.mtbio.2025.102584_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"Suppl 2","key":"10.1016\/j.mtbio.2025.102584_bib23","article-title":"958 BNT211: a phase I\/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors","volume":"9","author":"Mackensen","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2025.102584_bib25","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.201700375","article-title":"State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery","volume":"2","author":"Evers","year":"2018","journal-title":"Small Methods"},{"key":"10.1016\/j.mtbio.2025.102584_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"11","key":"10.1016\/j.mtbio.2025.102584_bib28","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib29","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1021\/acs.bioconjchem.0c00366","article-title":"The biomolecular corona of lipid nanoparticles for gene therapy","volume":"31","author":"Francia","year":"2020","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.mtbio.2025.102584_bib30","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.mtbio.2025.102584_bib31","article-title":"A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes","volume":"32","author":"Ramishetti","year":"2020","journal-title":"Adv. Mater."},{"issue":"19","key":"10.1016\/j.mtbio.2025.102584_bib32","article-title":"A combinatorial library of lipid nanoparticles for cell type\u2010specific MRNA delivery","volume":"10","author":"Naidu","year":"2023","journal-title":"Adv. Sci."},{"issue":"6","key":"10.1016\/j.mtbio.2025.102584_bib33","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1021\/acsnano.4c18636","article-title":"Ionizable lipids with optimized linkers enable lung-specific, lipid nanoparticle-mediated mRNA delivery for treatment of metastatic lung tumors","volume":"19","author":"Somu Naidu","year":"2025","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"18","key":"10.1016\/j.mtbio.2025.102584_bib35","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1021\/bi00018a025","article-title":"Transbilayer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes","volume":"34","author":"Rodrigueza","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.mtbio.2025.102584_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","article-title":"PEG \u2013 a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J. Contr. Release"},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib37","article-title":"Lipid nanoparticles with fine\u2010tuned composition show enhanced Colon targeting as a platform for mRNA therapeutics","volume":"12","author":"Rampado","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mtbio.2025.102584_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"45","key":"10.1016\/j.mtbio.2025.102584_bib39","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11095-012-0874-6","article-title":"Effect of PEGylation on biodistribution and gene silencing of siRNA\/lipid nanoparticle complexes","volume":"30","author":"Bao","year":"2013","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Lila","year":"2013","journal-title":"J. Contr. Release"},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2025.102584_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.addr.2020.06.014","article-title":"Polymeric vehicles for nucleic acid delivery","volume":"156","author":"Piotrowski-Daspit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2025.102584_bib46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib47","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2025.102584_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101738","article-title":"Poly (ethylene glycol) alternatives in biomedical applications","volume":"48","author":"Yao","year":"2023","journal-title":"Nano Today"},{"issue":"8","key":"10.1016\/j.mtbio.2025.102584_bib49","article-title":"Poly (N\u2010methyl\u2010N\u2010vinylacetamide): a strong alternative to PEG for lipid\u2010based nanocarriers delivering siRNA","volume":"13","author":"Berger","year":"2024","journal-title":"Adv. Healthcare Mater."},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202207471","article-title":"An integrated polymeric mRNA vaccine without inflammation side effects for cellular immunity\u2013mediated cancer therapy","volume":"35","author":"Huang","year":"2023","journal-title":"Adv. Mater."},{"issue":"50","key":"10.1016\/j.mtbio.2025.102584_bib51","doi-asserted-by":"crossref","first-page":"21321","DOI":"10.1021\/jacs.1c09822","article-title":"Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mtbio.2025.102584_bib52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejpb.2021.03.011","article-title":"Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination","volume":"163","author":"Zhang","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.biomaterials.2011.09.061","article-title":"Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors","volume":"33","author":"Zhou","year":"2012","journal-title":"Biomaterials"},{"issue":"21","key":"10.1016\/j.mtbio.2025.102584_bib54","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1016\/j.biomaterials.2010.03.069","article-title":"Surface functionalisation of PLGA nanoparticles for gene silencing","volume":"31","author":"Andersen","year":"2010","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mtbio.2025.102584_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/794528","article-title":"RNA-based vaccines in cancer immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J. Immunol. Res."},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib57","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3390\/pharmaceutics13091391","article-title":"Delivery of various cargos into cancer cells and tissues via cell-penetrating peptides: a review of the last decade","volume":"13","author":"Shoari","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2025.102584_bib58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.peptides.2018.04.015","article-title":"Cell-penetrating peptides for siRNA delivery to glioblastomas","volume":"104","author":"Srimanee","year":"2018","journal-title":"Peptides"},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib59","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1093\/nar\/gkq1299","article-title":"Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo","volume":"39","author":"El Andaloussi","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mtbio.2025.102584_bib60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.actbio.2017.06.032","article-title":"Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells","volume":"59","author":"Wan","year":"2017","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymthe.2016.10.006","article-title":"A targeted and stable polymeric nanoformulation enhances systemic delivery of mRNA to tumors","volume":"25","author":"Chen","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2025.102584_bib62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejpb.2019.05.014","article-title":"Peptide-mediated delivery of therapeutic mRNA in ovarian cancer","volume":"141","author":"van den Brand","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.mtbio.2025.102584_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2019.08.002","article-title":"Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine","volume":"310","author":"Tateshita","year":"2019","journal-title":"J. Contr. Release"},{"issue":"44","key":"10.1016\/j.mtbio.2025.102584_bib64","doi-asserted-by":"crossref","first-page":"13808","DOI":"10.1002\/anie.201608450","article-title":"Polymer\u2013lipid nanoparticles for systemic delivery of mRNA to the lungs","volume":"55","author":"Kaczmarek","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"6478","key":"10.1016\/j.mtbio.2025.102584_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2025.102584_bib66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.mtbio.2025.102584_bib67","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-17-0827","article-title":"Anti-HER2 scFv-directed extracellular vesicle\u2013mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108211","article-title":"Synthetic transcription factors establish the function of nine amino acid transactivation domains of Komagataella phaffii Mxr1","volume":"301","author":"Priya","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib70","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41467-018-03733-8","article-title":"Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment","volume":"9","author":"Kojima","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib71","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","article-title":"Linkage between endosomal escape of LNP\u2013mRNA and loading into EVs for transport to other cells","volume":"10","author":"Maugeri","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.mtbio.2025.102584_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101266","article-title":"Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity","volume":"297","author":"Tsai","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib73","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/pharmaceutics14020267","article-title":"Extracellular vesicle-based hybrid systems for advanced drug delivery","volume":"14","author":"Rodr\u00edguez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2025.102584_bib74","article-title":"Engineering hybrid exosomes by membrane fusion with liposomes","volume":"6","author":"Sato","year":"2016","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.mtbio.2025.102584_bib75","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/adma.201204346","article-title":"Degradable terpolymers with alkyl side chains demonstrate enhanced gene delivery potency and nanoparticle stability","volume":"25","author":"Eltoukhy","year":"2013","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2025.102584_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","article-title":"Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination","volume":"125","author":"Persano","year":"2017","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.mtbio.2025.102584_bib77","doi-asserted-by":"crossref","first-page":"13015","DOI":"10.1021\/acsomega.9b00489","article-title":"Co-delivery of mRNA with \u03b1-galactosylceramide using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration","volume":"4","author":"Guevara","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.mtbio.2025.102584_bib78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2018.03.035","article-title":"Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells","volume":"278","author":"Le Moignic","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2025.102584_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1037051","article-title":"mRNA therapy for myocardial infarction: a review of targets and delivery vehicles","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"8","key":"10.1016\/j.mtbio.2025.102584_bib80","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17425247.2022.2108786","article-title":"Recent advances in erythrocyte membrane-camouflaged nanoparticles for the delivery of anti-cancer therapeutics","volume":"19","author":"Wang","year":"2022","journal-title":"Expet Opin. Drug Deliv."},{"issue":"27","key":"10.1016\/j.mtbio.2025.102584_bib81","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2025.102584_bib82","article-title":"Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance","volume":"18","author":"Chai","year":"2025","journal-title":"Drug Resist. Updates"},{"issue":"7","key":"10.1016\/j.mtbio.2025.102584_bib83","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3390\/pharmaceutics15071899","article-title":"Recent advances in cell membrane coated-nanoparticles as drug delivery systems for tackling urological diseases","volume":"15","author":"Yao","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2025.102584_bib84","unstructured":"ModernaTX, Inc. Repeat-Dose Study of mRNA-3927 in Participants with Cystic Fibrosis (NCT05668741). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib85","unstructured":"ModernaTX, Inc. Phase 1\/2 Study of Intratumoral mRNA-2752 for relapsed\/refractory Lymphoma (NCT05712538). ClinicalTrials.gov."},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib86","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct intramyocardial injection of VEGF-A mRNA in patients undergoing coronary artery bypass surgery: a randomized, controlled phase 2 trial","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol. Ther."},{"issue":"10427","key":"10.1016\/j.mtbio.2025.102584_bib87","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.mtbio.2025.102584_bib88","series-title":"Announces Positive Topline Phase 2 Results for Mrna Cancer Vaccine Candidate BNT111 in Advanced Melanoma","author":"BioNTech","year":"2024"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib89","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-022-01528-6","article-title":"RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics","volume":"21","author":"Pandey","year":"2022","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib90","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced Melanoma, non\u2013small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"issue":"699","key":"10.1016\/j.mtbio.2025.102584_bib91","article-title":"Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination","volume":"15","author":"Suberi","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib92","article-title":"Lung-delivered IL-10 mitigates lung inflammation induced by repeated endotoxin exposures in male mice","volume":"13","author":"Schwab","year":"2025","journal-title":"Phys. Rep."},{"issue":"35","key":"10.1016\/j.mtbio.2025.102584_bib93","article-title":"Rapid generation of circulating and mucosal decoy human ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2","volume":"9","author":"Kim","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.mtbio.2025.102584_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102515","article-title":"mRNA-encoded ACE2 decoy lipid nanoparticles for neutralizing SARS-CoV-2 variants","volume":"36","author":"Guimar\u00e3es","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib95","first-page":"600","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle\u2013encapsulated mRNA vaccine","volume":"30","author":"Pardi","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2025.102584_bib96","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbaf023","article-title":"Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues","volume":"12","author":"Wang","year":"2025","journal-title":"Regen. Biomater."},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib97","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2174\/1567201819666220613145417","article-title":"Hepatocyte growth factor delivered by nanocomposites for gene therapy of bleomycin-induced pulmonary fibrosis in rats","volume":"20","author":"Guo","year":"2023","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.mtbio.2025.102584_bib98","unstructured":"ModernaTX, Inc. Phase 1\/2 Study of CAR-T Cell Therapy BNT211 (CLDN6 CAR-T) plus Carvac in Solid Tumors (NCT04503278). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib99","article-title":"Gastrointestinal delivery of mRNA lipid nanoparticles selectively targets the pancreas","author":"Abbas","year":"2025","journal-title":"bioRxiv [Preprint]"},{"key":"10.1016\/j.mtbio.2025.102584_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113588","article-title":"Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma","volume":"381","author":"Shen","year":"2025","journal-title":"J. Contr. Release"},{"issue":"6576","key":"10.1016\/j.mtbio.2025.102584_bib101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2025.102584_bib102","series-title":"RNA Therapeutics","article-title":"Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens","author":"Alameh","year":"2022"},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib103","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mtbio.2025.102584_bib104","article-title":"Delivery of hepatocyte growth factor messenger RNA by lipid nanoparticles promotes lung tissue regeneration and repair in Emphysema","volume":"211","author":"Chen","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cac2.12511","article-title":"Rescue of p53 functions by in vitro\u2013transcribed mRNA impedes the growth of high-grade serous ovarian cancer","volume":"44","author":"Raab","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.mtbio.2025.102584_bib106","unstructured":"BioNTech SE. A Phase 1\/2 study of mRNA-based CAR T cell therapy (BNT116) in patients with CLDN6-positive relapsed or refractory advanced solid tumors. ClinicalTrials.gov ID: NCT05142189."},{"key":"10.1016\/j.mtbio.2025.102584_bib107","unstructured":"ModernaTX, Inc. Phase 1\/2 Study of CAR-T Cell Therapy BNT211 (CLDN6 CAR-T) plus CARVac in Solid Tumors (NCT04503278). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib109","unstructured":"Amgen, Inc. Phase 2 Trial of Maridebart Cafraglutide in Type 2 Diabetes (NCT04891584). Amgen Study Listing."},{"key":"10.1016\/j.mtbio.2025.102584_bib110","unstructured":"ModernaTX, Inc. Phase 1\/2 Study of Intratumoral mRNA-2752 for Relapsed\/Refractory Lymphoma and Myeloma (NCT03739931). ClinicalTrials.gov."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib111","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.devcel.2013.05.018","article-title":"Adult duct-lining cells can reprogram into \u03b2-like cells able to counter repeated cycles of toxin-induced diabetes","volume":"26","author":"Al-Hasani","year":"2013","journal-title":"Dev. Cell"},{"key":"10.1016\/j.mtbio.2025.102584_bib112","series-title":"A multi-system Approach to Define Regulatory Mechanisms of Alveolar Progenitors in Development, Disease, and Regeneration","author":"Toth","year":"2023"},{"issue":"7","key":"10.1016\/j.mtbio.2025.102584_bib113","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1021\/acs.biomac.4c00651","article-title":"Tailored monoacyl poly(2-oxazoline)- and poly(2-oxazine)-lipids as PEG-lipid alternatives for stabilization and delivery of mRNA\u2013lipid nanoparticles","volume":"25","author":"He","year":"2024","journal-title":"Biomacromolecules"},{"issue":"11","key":"10.1016\/j.mtbio.2025.102584_bib115","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2025.102584_bib116","series-title":"Molecular Cell Biology","author":"Lodish","year":"2016"},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib117","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrm908","article-title":"Seven-transmembrane receptors","volume":"3","author":"Pierce","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib118","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2025.102584_bib119","series-title":"Pharmacology in Drug Discovery and Development","author":"Kenakin","year":"2012"},{"issue":"11","key":"10.1016\/j.mtbio.2025.102584_bib120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib122","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/ar7000815","article-title":"Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases","volume":"41","author":"Low","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.mtbio.2025.102584_bib123","article-title":"Advances in receptor-targeted nanocarriers for cancer therapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.mtbio.2025.102584_bib124","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12951-025-03639-w","article-title":"Blood\u2013brain barrier-penetrating Angiopep-2\/Sirtuin 1 nanoparticles rescue sevoflurane neurotoxicity through multi-omics identified necroptosis pathways","volume":"23","author":"Chang","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib126","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/polym14040712","article-title":"Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: a review","volume":"14","author":"Habib","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.mtbio.2025.102584_bib127","article-title":"Peptide-functionalized nanoparticles for brain-targeted therapeutics","author":"Tang","year":"2025","journal-title":"Drug Deliv Transl Res"},{"issue":"8","key":"10.1016\/j.mtbio.2025.102584_bib128","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2008.127","article-title":"Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers","volume":"16","author":"Muro","year":"2008","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2967\/jnumed.107.045302","article-title":"In vivo imaging of \u02c664Cu-labeled polymer nanoparticles targeted to the lung endothelium","volume":"49","author":"Rossin","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.mtbio.2025.102584_bib130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fonc.2013.00216","article-title":"Tumor-penetrating peptides","volume":"3","author":"Teesalu","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mtbio.2025.102584_bib131","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.17584","article-title":"Reproducibility project: cancer biology. Replication study: coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"6","author":"Mantis","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.mtbio.2025.102584_bib132","article-title":"Engineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines","volume":"34","author":"Wang","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.mtbio.2025.102584_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2025.100180","article-title":"A precision-engineered dendritic cell-targeted mRNA nanovaccine for enhanced antiviral immunity","author":"Qin","year":"2025","journal-title":"Cell Biomater"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib134","first-page":"142","article-title":"Identification of targeting peptides for ischemic myocardium (CSTSMLKAC)","volume":"50","author":"Ishihara","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"20","key":"10.1016\/j.mtbio.2025.102584_bib135","article-title":"Engineered exosomes with ischemic myocardium-targeting peptide","volume":"8","author":"Gao","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.mtbio.2025.102584_bib136","article-title":"A versatile antibody capture system drives specific in vivo delivery of mRNA-LNPs","author":"Pouton","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2025.102584_bib137","article-title":"Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell markers","volume":"30","author":"Tiwari","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"4968","key":"10.1016\/j.mtbio.2025.102584_bib138","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.mtbio.2025.102584_bib139","article-title":"Oligonucleotide aptamers: new tools for targeted cancer therapy","volume":"3","author":"Sun","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yexmp.2009.01.004","article-title":"Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer","volume":"86","author":"Bates","year":"2009","journal-title":"Exp. Mol. Pathol."},{"issue":"6","key":"10.1016\/j.mtbio.2025.102584_bib141","first-page":"643","article-title":"Nanoparticle\u2013aptamer bioconjugates for cancer targeting","volume":"3","author":"Farokhzad","year":"2006","journal-title":"Expet Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib142","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.mtbio.2025.102584_bib143","doi-asserted-by":"crossref","first-page":"13624","DOI":"10.3390\/s131013624","article-title":"Aptamers as theranostic agents: modifications, serum stability and functionalisation","volume":"13","author":"Shigdar","year":"2013","journal-title":"Sensors (Basel)"},{"key":"10.1016\/j.mtbio.2025.102584_bib144","first-page":"122","article-title":"Aptamer-based targeted drug delivery systems: current status and future perspectives","volume":"138","author":"Wang","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.mtbio.2025.102584_bib145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib146","first-page":"683","article-title":"Untranslated regions of mRNA in regulation of gene expression","volume":"19","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2025.102584_bib147","first-page":"477","article-title":"MicroRNA-mediated regulation of mRNA stability and translation: a comprehensive view","volume":"10","author":"Cheng","year":"2019","journal-title":"Front. Genet."},{"issue":"12","key":"10.1016\/j.mtbio.2025.102584_bib148","first-page":"1025","article-title":"Codon optimization in mRNA therapeutics: influence on translation efficiency and immune modulation","volume":"41","author":"Kumar","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mtbio.2025.102584_bib149","article-title":"Tissue-specific gene delivery using engineered promoters and transcription factors","volume":"44","author":"Kwon","year":"2020","journal-title":"Biotechnol. Adv."},{"issue":"7830","key":"10.1016\/j.mtbio.2025.102584_bib150","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib151","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib152","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.mtbio.2025.102584_bib153","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1088\/0022-3727\/36\/13\/201","article-title":"Applications of magnetic nanoparticles in biomedicine","volume":"36","author":"Pankhurst","year":"2003","journal-title":"J. Phys. D Appl. Phys."},{"key":"10.1016\/j.mtbio.2025.102584_bib154","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.2147\/IJN.S30320","article-title":"Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers","volume":"6","author":"Wahajuddin","year":"2012","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib155","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/wnan.1311","article-title":"Open challenges in magnetic drug targeting","volume":"7","author":"Shapiro","year":"2015","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"18","key":"10.1016\/j.mtbio.2025.102584_bib156","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1016\/j.biomaterials.2004.10.012","article-title":"Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications","volume":"26","author":"Gupta","year":"2005","journal-title":"Biomaterials"},{"issue":"1\u20133","key":"10.1016\/j.mtbio.2025.102584_bib157","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0304-8853(99)00088-8","article-title":"Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field\u2013induced excitation of biocompatible superparamagnetic nanoparticles","volume":"201","author":"Jordan","year":"1999","journal-title":"J. Magn. Magn Mater."},{"key":"10.1016\/j.mtbio.2025.102584_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202400176","article-title":"Magnetic multifunctional nanoparticles for effective targeted cancer therapy","author":"Miao","year":"2025","journal-title":"Adv. NanoBiomed. Res."},{"issue":"10","key":"10.1016\/j.mtbio.2025.102584_bib159","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.addr.2008.03.008","article-title":"Micelles and nanoparticles for ultrasonic drug and gene delivery","volume":"60","author":"Husseini","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2025.102584_bib160","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.2147\/OTT.S94800","article-title":"Ultrasound-guided RNA interference targeting HIF-1 alpha improves the effects of transarterial chemoembolization in rat liver tumors","volume":"27","author":"Chen","year":"2015","journal-title":"OncoTargets Ther."},{"issue":"1\u20132","key":"10.1016\/j.mtbio.2025.102584_bib161","first-page":"3","article-title":"Microbubble compositions, properties and biomedical applications","volume":"1","author":"Sirsi","year":"2014","journal-title":"Bubble Sci. Eng. Technol."},{"issue":"5","key":"10.1016\/j.mtbio.2025.102584_bib162","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/wnan.1176","article-title":"Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer","volume":"4","author":"Rapoport","year":"2012","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib163","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-80933-x","article-title":"Development of an inhalable contrast agent targeting the respiratory tract mucus layer for pulmonary ultrasonic imaging","volume":"14","author":"Tsuruta","year":"2024","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.mtbio.2025.102584_bib164","first-page":"4641","article-title":"Ultrasound-triggered drug delivery for cancer therapy","volume":"8","author":"Zhou","year":"2018","journal-title":"Theranostics"},{"issue":"20","key":"10.1016\/j.mtbio.2025.102584_bib165","first-page":"3013","article-title":"Microfluidic technologies for lipid nanoparticle fabrication and targeted drug delivery","volume":"18","author":"Maeki","year":"2018","journal-title":"Lab Chip"},{"issue":"3","key":"10.1016\/j.mtbio.2025.102584_bib166","first-page":"115","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"29","author":"Kulkarni","year":"2019","journal-title":"Nucleic Acid Therapeut."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib167","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1021\/acsnano.4c12965","article-title":"Robust, scalable microfluidic manufacturing of RNA\u2013lipid nanoparticles using immobilized antifouling lubricant coating","volume":"19","author":"Hwang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2025.102584_bib168","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Contr. Release"},{"issue":"12","key":"10.1016\/j.mtbio.2025.102584_bib169","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"42","key":"10.1016\/j.mtbio.2025.102584_bib170","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mtbio.2025.102584_bib171","first-page":"1","article-title":"Emerging polymeric and hybrid nanocarriers for mRNA delivery","volume":"160","author":"Rasmussen","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib172","first-page":"201","article-title":"Lyophilization of lipid nanoparticles for mRNA vaccines: challenges and opportunities","volume":"39","author":"Kim","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.mtbio.2025.102584_bib173","article-title":"mRNA vaccine development: recent progress and future perspectives","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib174","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s42003-024-06235-0","article-title":"Overcoming thermostability challenges in mRNA\u2013lipid nanoparticle systems with piperidine-based ionizable lipids","volume":"7","author":"Hashiba","year":"2024","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib175","first-page":"365","article-title":"The current status of mRNA vaccine development against SARS-CoV-2","volume":"20","author":"Lundstrom","year":"2021","journal-title":"Expert Rev. Vaccines"},{"issue":"10","key":"10.1016\/j.mtbio.2025.102584_bib176","first-page":"6700","article-title":"Deconvoluting lipid nanoparticle structure for messenger RNA delivery","volume":"20","author":"Eygeris","year":"2020","journal-title":"Nano Lett."},{"issue":"12","key":"10.1016\/j.mtbio.2025.102584_bib177","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2025.102584_bib178","series-title":"Lipid Nanoparticle Drug Products: Chemistry, Manufacturing, and Control Information (Guidance for Industry)","year":"2020"},{"key":"10.1016\/j.mtbio.2025.102584_bib179","article-title":"Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product","volume":"2","year":"2018","journal-title":"EMA\/CHMP\/SWP\/72894\/2007 Rev."},{"key":"10.1016\/j.mtbio.2025.102584_bib180","series-title":"ICH Harmonised Guideline: Pharmaceutical Development Q8(R2), Quality Risk Management Q9, Pharmaceutical Quality System Q10","author":"Ich","year":"2020"},{"key":"10.1016\/j.mtbio.2025.102584_bib181","series-title":"FDA Approves First COVID-19 Vaccine (Press Announcement)","year":"2021"},{"key":"10.1016\/j.mtbio.2025.102584_bib182","series-title":"Assessment Report: Spikevax","year":"2021"},{"key":"10.1016\/j.mtbio.2025.102584_bib183","series-title":"CureVac Provides Update on COVID-19 Vaccine CVnCoV","author":"CureVac","year":"2021"},{"issue":"8009","key":"10.1016\/j.mtbio.2025.102584_bib184","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","article-title":"Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia","volume":"628","author":"Koeberl","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2025.102584_bib185","series-title":"Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. FDA for START Pilot Program (Press Release)","year":"2024"},{"issue":"6","key":"10.1016\/j.mtbio.2025.102584_bib186","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/j.ymthe.2025.03.034","article-title":"Clinical development of therapeutic mRNA applications","volume":"33","author":"\u017bak","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2025.102584_bib187","series-title":"Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency","author":"Therapeutics","year":"2025"},{"key":"10.1016\/j.mtbio.2025.102584_bib188","article-title":"Trial details: mRNA-3210-P101 (Propionic Acidemia)","year":"2025","journal-title":"Moderna Trial Listing"},{"key":"10.1016\/j.mtbio.2025.102584_bib189","series-title":"Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an Mrna Therapeutic for Ultra-rare Disease, Crigler-Najjar syndrome Type 1 (Press Release)","year":"2021"},{"issue":"12","key":"10.1016\/j.mtbio.2025.102584_bib190","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2025.102584_bib191","article-title":"Exosome-based nanoplatform for LDLR mRNA delivery in familial hypercholesterolemia (ENDEAVOUR trial, NCT05043181)","year":"2021","journal-title":"MedPath Clinical Trial Listing"},{"key":"10.1016\/j.mtbio.2025.102584_bib192","article-title":"Orna therapeutics","year":"2024","journal-title":"Our Pipeline"},{"key":"10.1016\/j.mtbio.2025.102584_bib193","series-title":"Capstan Therapeutics Presents Preclinical Data on Lead in Vivo CAR-T Candidate, CPTX2309, at ACR Convergence 2024 (Press Release). Nov 18","author":"Acevedo","year":"2024"},{"key":"10.1016\/j.mtbio.2025.102584_bib194","series-title":"Science & Platform","year":"2024"},{"key":"10.1016\/j.mtbio.2025.102584_bib195","series-title":"Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for OTC Deficiency (Press Release)","year":"2023"},{"key":"10.1016\/j.mtbio.2025.102584_bib196","unstructured":"National Library of Medicine. Open-Label Study of mRNA-3927 in Participants with Propionic Acidemia (NCT04159103). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib197","unstructured":"National Library of Medicine. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults (NCT03829384). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib198","unstructured":"National Library of Medicine. Study of mRNA-3704 for Methylmalonic Acidemia (NCT04899310). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib199","unstructured":"National Library of Medicine. Study of mRNA-3131 for Ornithine Transcarbamylase Deficiency (NCT06488313). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib200","unstructured":"National Library of Medicine. RESTORE-CF: Nebulized MRT5005 in Adults with Cystic Fibrosis (NCT03375047). ClinicalTrials.gov."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib201","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1038\/s41467-024-47460-9","article-title":"Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria","volume":"15","author":"Baek","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2025.102584_bib202","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.975408","article-title":"An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma","volume":"12","author":"Deng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mtbio.2025.102584_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114993","article-title":"mRNA: a promising platform for cancer immunotherapy","volume":"199","author":"Kong","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"16 Suppl","key":"10.1016\/j.mtbio.2025.102584_bib204","article-title":"Abstract CT032: a phase 1\/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416 (LNP encapsulated OX40L mRNA) alone or with durvalumab for patients with advanced malignancies","volume":"80","author":"Jimeno","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2025.102584_bib205","unstructured":"National Library of Medicine. Personalized Cancer Vaccine mRNA-4157 plus Pembrolizumab Vs. Pembrolizumab Alone After Resection of Melanoma (KEYNOTE-942, NCT03897881). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtn.2023.06.023","article-title":"Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine transcarbamylase deficiency model mice","volume":"33","author":"Yamazaki","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib207","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-023-37465-1","article-title":"GalNAc-lipid nanoparticles enable non-LDLR-dependent hepatic delivery of a CRISPR base editing therapy","volume":"14","author":"Kasiewicz","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib208","article-title":"N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs","volume":"12","author":"Chen","year":"2022","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib209","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1021\/acs.nanolett.7b02664","article-title":"Boosting intracellular delivery of lipid nanoparticle\u2013encapsulated mRNA","volume":"17","author":"Patel","year":"2017","journal-title":"Nano Lett."},{"issue":"48","key":"10.1016\/j.mtbio.2025.102584_bib210","article-title":"Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering","volume":"34","author":"Mukalel","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"8","key":"10.1016\/j.mtbio.2025.102584_bib211","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1073\/pnas.1620874114","article-title":"Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics","volume":"114","author":"Dahlman","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib212","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.mtbio.2025.102584_bib213","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btae342","article-title":"Representations of lipid nanoparticles using large language models for transfection efficiency prediction","volume":"40","author":"Moayedpour","year":"2024","journal-title":"Bioinformatics"},{"key":"10.1016\/j.mtbio.2025.102584_bib214","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1501010","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.mtbio.2025.102584_bib215","unstructured":"Ding DY, Zhang Y, Jia Y, Sun J. Machine learning\u2013guided lipid nanoparticle design for mRNA delivery. arXiv [Preprint]. Posted August 3, 2023. arXiv:2308.01402. DOI: 10.48550\/arXiv.2308.01402."},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib216","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/biochem5020005","article-title":"Advances in personalized cancer vaccine development: AI applications from neoantigen discovery to mRNA formulation","volume":"5","author":"Kong","year":"2025","journal-title":"BioChemistry"},{"issue":"5","key":"10.1016\/j.mtbio.2025.102584_bib217","first-page":"3027","article-title":"Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mtbio.2025.102584_bib218","article-title":"Rational design of lipid nanoparticles for enhanced mRNA vaccine delivery via machine learning","author":"Bae","year":"2024","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.mtbio.2025.102584_bib219","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-viral CRISPR\/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"issue":"6","key":"10.1016\/j.mtbio.2025.102584_bib220","first-page":"1604","article-title":"mRNA and gene editing: late-breaking therapies in liver diseases","volume":"75","author":"Zabaleta","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.mtbio.2025.102584_bib221","article-title":"Nanoparticle-formulated mRNA encoding engineered multivalent SIRP\u03b1-Fc fusion proteins shows robust anti-cancer activity in preclinical models","volume":"30","author":"Lal","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"17","key":"10.1016\/j.mtbio.2025.102584_bib222","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.mtbio.2025.102584_bib223","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.3390\/ijms26094420","article-title":"CRISPR\/Cas9 delivery systems to enhance gene editing efficiency","volume":"26","author":"Seijas","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"6701","key":"10.1016\/j.mtbio.2025.102584_bib224","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.adk9428","article-title":"In vivo editing of lung stem cells for durable gene correction in mice","volume":"384","author":"Sun","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib225","first-page":"160","article-title":"Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseases","volume":"16","author":"O'Donnell","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.mtbio.2025.102584_bib226","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2025.102584_bib227","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jconrel.2022.01.047","article-title":"Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy","volume":"343","author":"Yoo","year":"2022","journal-title":"J. Contr. Release"},{"issue":"13","key":"10.1016\/j.mtbio.2025.102584_bib228","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310514","article-title":"mRNA: vaccine or gene therapy? The safety regulatory issues","volume":"24","author":"Banoun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2025.102584_bib229","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1429265","article-title":"Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19","volume":"12","author":"Iqbal","year":"2024","journal-title":"Front. Public Health"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12967-019-02154-5","article-title":"A few ethical issues in translational research for gene and cell therapy","volume":"17","author":"Riva","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mtbio.2025.102584_bib231","first-page":"311","article-title":"Biosafety and regulatory issues of RNA therapeutics","volume":"189","author":"Hue","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.mtbio.2025.102584_bib232","unstructured":"National Library of Medicine. A Study of mRNA-3745 in Glycogen Storage Disease Type 1a (NCT05095727). ClinicalTrials.gov."},{"key":"10.1016\/j.mtbio.2025.102584_bib233","series-title":"A Study of AZD8601 in Patients with Heart Failure Undergoing Coronary Artery Bypass Grafting (EPICCURE)","year":"2023"},{"issue":"1","key":"10.1016\/j.mtbio.2025.102584_bib234","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259000642501155X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259000642501155X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:05:23Z","timestamp":1773871523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259000642501155X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":232,"alternative-id":["S259000642501155X"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2025.102584","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2025.102584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102584"}}